ASCO 2016: Updated Data of MOR202 for Multiple Myeloma Presented by MorphoSys
In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Clinical Results of Selinexor Combo Regimen for Multiple Myeloma Presented by Moffitt Cancer Cancer at ASCO 2016
The Moffitt Cancer Center has completed a Phase 1 clinical trial of selinexor combined with liposomal doxorubicin and dexamethasone for the treatment of…
European Commission Approves Janssen’s Multiple Myeloma Treatment Darzalex (Daratumumab)
The European Commission (EC) has granted provisional approval to Janssen’s Darzalex (daratumumab) as a monotherapy for the treatment of patients with multiple myeloma who…
New Clinical Trial for Multiple Myeloma Patients to Evaluate Safety and Efficacy of SurVaxM Vaccine
An immune-based vaccine created by researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) is now moving to its third study. The new…
Iceni Planning a Phase 2 Study of Cilengitide in Multiple Myeloma Patients
Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple…
Myeloma Foundation Claims Controversial Drug Report Could Limit Access to Best Treatments
The International Myeloma Foundation (IMF), the largest organization focusing specifically on multiple myeloma (MM), is now alerting that a reportedly flawed document evaluating…
